News

Vast US market opportunity seen for Proteomics kidney test – The West Australian

Research by independent consultant Boston Healthcare Associates modelling the budget impact of PromarkerD versus existing care standards says US public and private health insurers could save US$384 billion over a decade.

Management says some 31 million diabetics in America are at risk of developing DKD. PromarkerD uses a simple blood test to detect the early onset of DKD in patients with type 2 diabetes. Early and cost-effective prediction could reduce the need for expensive treatment at later stages of the disease such as dialysis and kidney transplants.

Article: Vast US market opportunity seen for Proteomics kidney test

Subscribe
  • This field is for validation purposes and should be left unchanged.